牛牛AI助理已提取核心訊息
On February 13, 2024, Matsuda Masaru, associated with Arcutis Biotherapeutics, Inc. [ARQT], engaged in multiple transactions involving the acquisition of the company's common stock. The transactions, all classified under the code 'A' indicating grants, awards, or other acquisitions, resulted in a total of 119,550 shares being added to Masaru's direct holdings. The first transaction added 74,000 shares, the second 17,650 shares, and the third 27,900 shares. Following these acquisitions, Masaru's beneficial ownership of Arcutis Biotherapeutics' common stock increased to 194,184 shares. The transactions reflect a positive action status, with the shares being directly held by Masaru.
On February 13, 2024, Matsuda Masaru, associated with Arcutis Biotherapeutics, Inc. [ARQT], engaged in multiple transactions involving the acquisition of the company's common stock. The transactions, all classified under the code 'A' indicating grants, awards, or other acquisitions, resulted in a total of 119,550 shares being added to Masaru's direct holdings. The first transaction added 74,000 shares, the second 17,650 shares, and the third 27,900 shares. Following these acquisitions, Masaru's beneficial ownership of Arcutis Biotherapeutics' common stock increased to 194,184 shares. The transactions reflect a positive action status, with the shares being directly held by Masaru.
2024年2月13日，與Arcutis Biotherapeutics, Inc. [ARQT] 相關的松田勝進行了多筆涉及收購該公司普通股的交易。這些交易全部歸類爲 “A”，表示補助、獎勵或其他收購，使Masaru的直接持股總共增加了119,550股股份。第一筆交易增加了74,000股，第二筆交易增加了17,650股，第三筆交易增加了27,900股。在這些收購之後，Masaru對Arcutis Biotherapeutics普通股的實益所有權增加到194,184股。這些交易反映了積極的行動狀態，股票由Masaru直接持有。
2024年2月13日，與Arcutis Biotherapeutics, Inc. [ARQT] 相關的松田勝進行了多筆涉及收購該公司普通股的交易。這些交易全部歸類爲 “A”，表示補助、獎勵或其他收購，使Masaru的直接持股總共增加了119,550股股份。第一筆交易增加了74,000股，第二筆交易增加了17,650股，第三筆交易增加了27,900股。在這些收購之後，Masaru對Arcutis Biotherapeutics普通股的實益所有權增加到194,184股。這些交易反映了積極的行動狀態，股票由Masaru直接持有。
有用
沒用